This is the authors' abstract. We don't add key points for this paper.
To the Editor: Between the time of the initial marketing of alendronate in October 1995 through mid-May 2008, the Food and Drug Administration (FDA) received reports of 23 patients in the United States receiving a diagnosis of esophageal cancer, with alendronate (Fosamax, Merck) as the suspect drug (in 21 patients) or the concomitant drug (in 2 patients). No similar U.S. reports for other oral bisphosphonates were retrieved from the FDA's database for adverse-event reporting. Eight deaths were reported. Of the 23 patients, 18 (78%) were women; the median age was 74.0 years (mean, 71.8; based on 19 patients). Among the . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Diane K. Wysowski (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: